Skip to content

New Drug Fights Advanced Prostate Cancer

Cabazitaxel Extends Lives of Men With No More Treatment Options
Font Size
A
A
A
By
WebMD Health News
Reviewed by Louise Chang, MD

March 3, 2010 -- A new drug shows promise for extending the lives of men with advanced prostate cancer who have run out of treatment options.

In a large study, men given the experimental drug, called cabazitaxel, lived an average of just over 15 months, while those given standard chemotherapy lived an average of nearly 13 months.

Living an extra two or three months might not sound like much, but all the men had prostate cancer that had spread throughout the body despite standard treatment, says study head Oliver Sartor, MD, a cancer researcher at Tulane Cancer Center in New Orleans.

"These men really don't have other alternatives," Sartor tells WebMD."They are only expected to live about a year. Cabazitaxel more than doubled the number of men that lived for at least two years."

As many as 20,000 men in the U.S. could benefit from the drug each year, he says.

Men with earlier prostate cancer might benefit even more, says American Society of Clinical Oncology (ASCO) spokesman Nicholas J. Vogelzang, MD, head of developmental therapeutics at U.S. Oncology in Las Vegas.

"These are impressive results. Advances in cancer are almost always incremental," he tells WebMD.

Vogelzang moderated a news briefing held in advance of the 2010 Genitourinary Cancers Symposium, sponsored by ASCO and two other major cancer groups.

Cabazitaxel for Prostate Cancer: How It Works

About 192,000 men were diagnosed with prostate cancer in 2009 and 27,360 men died of the disease, according to Sartor.

Cabazitaxel is a chemically modified form of the chemotherapy drug Taxotere. That's the drug of last resort for the 15,000 to 20,000 men with advanced prostate cancer that continues to spread despite treatment to reduce the production of the hormone testosterone that fuels prostate cancer cell growth.

But Taxotere also eventually stops working because prostate cancer cells pump the drug out before it can exert its effects, Sartor says.

The pump appears to be unable to recognize cabazitaxel, enabling the drug to enter and effectively kill the prostate cancer cells, he says.

Today on WebMD

man with doctor
Symptoms, risks, treatments
man coughing
Men shouldn’t ignore
 
prostate cancer cells
What does this diagnosis mean?
doctor and male patient
Is it worth it?
 
cancer fighting foods
SLIDESHOW
15 Cancer Symptoms Men Ignore
FEATURE
 
Prostate Enlarged
VIDEO
Picture Of The Prostate
ANATOMY
 
Prostate Cancer Quiz
QUIZ
screening tests for men
SLIDESHOW
 
Prostate Cancer Symptoms
VIDEO
Vitamin D
SLIDESHOW